
AZD1390 with radiotherapy shows manageable safety profile and preliminary efficacy for patients with glioblastoma
AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, demonstrated a manageable safety profile in both recurrent and newly diagnosed glioblastoma (GBM) patients when given in combination with standard-of-care radiotherapy ...
Apr 9, 2024
0
1